Saturday , October 23 2021

Caplin Point Laboratories gets nod for slump sale of regulated markets injectable business

Caplin Point Laboratories has received an approval for the slump sale of business undertaking of the Company (Regulated Markets Injectable Business, including USFDA approved Injectable plant) to its wholly owned subsidiary company which is in the process of being incorporated. The Board of Directors of the company at their meeting held on November 19, 2018, approved the same.

Caplin Point Laboratories is engaged mainly in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations.

Please share this news
<div id="taboola-below-article-thumbnails"></div>
<script type="text/javascript">
  window._taboola = window._taboola || [];
    mode: 'thumbnails-a',
    container: 'taboola-below-article-thumbnails',
    placement: 'Below Article Thumbnails',
    target_type: 'mix'